Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adenine nucleotide translocase lysine N-methyltransferase (ANTKMT)
- Target
- ANTKMT
- Molecular classification
- Enzyme, Protein-lysine N-methyltransferase, Mitochondrial protein, Posttranslational modification enzyme
01
Overview
ANTKMT (Adenine nucleotide translocase lysine N-methyltransferase, FAM173A) is a mitochondrial enzyme responsible for the specific trimethylation of Lys-52 on the adenine nucleotide translocase proteins ANT2 (SLC25A5) and ANT3 (SLC25A6), and likely ANT1 (SLC25A4). This methylation is constitutive and appears to regulate mitochondrial respiration rate, linking posttranslational modification to organelle bioenergetics. ANTKMT is encoded by the ANTKMT gene (HGNC:14152, formerly FAM173A/C16orf24), and is localized in the mitochondrial matrix where it functions as a protein-lysine N-methyltransferase. Trimethylation by ANTKMT is essential for proper ANT function, but its direct impact on disease risk or drug responsiveness has not been established in published literature. ANTKMT belongs to the lysine methyltransferase (KMT) family, a class of enzymes with emerging roles in cell metabolism, epigenetic regulation, and disease.
- Other names
- FAM173AC16orf24ANT-KMTProtein N-lysine methyltransferase FAM173AFamily with sequence similarity 173 member AMGC2494RJD7Adenine nucleotide translocase lysine N-methyltransferase
02
Mechanism of action
Not applicable (no known drugs target ANTKMT directly; general mechanism is lysine methylation of the substrate protein ANT)
03
Biological functions
Peptidyl-lysine trimethylationRegulation of mitochondrial respiration and bioenergetics (through methylation of ANT at Lys-52)Mitochondrial transport and metabolism (via modulation of ANT isoforms)Potential regulation of cell energy status
04
Disease associations
Other (no direct disease association reported, but enzymes of this class are generally linked to metabolism and mitochondrial function; methyltransferases have emerging roles in cancer and metabolic diseases but no direct evidence for ANTKMT in disease yet)
05
Safety considerations
None reported (No clinical studies or safety challenges related to ANTKMT inhibition or modulation; however, changes in mitochondrial methylation status could theoretically alter bioenergetics)
06
Biomarkers
None reported (Lys-52 trimethylation on ANT could serve as a potential functional biomarker for enzyme activity, but not clinically established)
Beyond the preview
Go deeper on Adenine nucleotide translocase lysine N-methyltransferase (ANTKMT).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adenine nucleotide translocase lysine N-methyltransferase (ANTKMT).